ENTO
GridAI Technologies Corp.2.9900
+0.1500+5.28%
Nov 28, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
10.05MP/E (TTM)
-Basic EPS (TTM)
-11.66Dividend Yield
0%Recent Filings
8-K
10-Q
8-K
8-K
Entero raises $500K via notes and warrants
Entero Therapeutics secured $500,000 in initial funding on October 17, 2025, via a private placement of a non-interest-bearing promissory note maturing in one year and one day, paired with warrants for 200,000 common shares at $2.50 each, exercisable post-stockholder approval. The deal allows up to $5 million total through subsequent closings, with proceeds earmarked for general corporate needs like working capital or acquisitions. Warrants expire five years after approval, but hinge on Nasdaq-compliant stockholder votes every 90 days if needed. This non-dilutive cash bolsters liquidity amid biotech pressures.
8-K
Entero acquires GridAI for AI grid tech
Entero Therapeutics closed a share exchange on September 30, 2025, acquiring 100% of GridAI Corp, which owns 75% of AMPX UK Holdings, for 424,348 common shares and 38,801,546 Series H preferred shares convertible into 38,801,546 common shares post-shareholder approval, granting sellers 82.5% ownership on a fully diluted basis. This positions Entero in the booming AI energy infrastructure market, leveraging GridAI's platform to manage grid-edge demand amid surging data center power needs. Sellers gain board seats and registration rights. Nasdaq compliance hinges on approval.
ABEO
Abeona Therapeutics Inc.
5.00-0.08
ATOS
Atossa Therapeutics, Inc.
0.72+0.01
CYTOF
Altamira Therapeutics Ltd.
0.07+0.00
ENTA
Enanta Pharmaceuticals, Inc.
14.85-0.02
ENTX
Entera Bio Ltd.
2.09+0.01
EXOZ
eXoZymes Inc.
12.52-1.78
GLTO
Galecto, Inc.
30.00-1.60
SLNO
Soleno Therapeutics, Inc.
49.50-0.45
TRDA
Entrada Therapeutics, Inc.
11.37+0.34
ZNTL
Zentalis Pharmaceuticals, Inc.
1.38-0.02